Valuation: Photocure ASA

Market Cap 1.55B 156M 137M 126M 117M 222M 14.83B 226M 1.52B 587M 7.28B 586M 573M 25.33B P/E 2026 *
16.9x
P/E 2027 * 34.4x
Enterprise Value 1.3B 132M 116M 106M 99.08M 187M 12.51B 191M 1.28B 495M 6.14B 494M 483M 21.37B EV / Sales 2026 *
1.98x
EV / Sales 2027 * 1.94x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.64%
1 month-16.37%
3 months-12.59%
6 months-11.71%
Current year-11.71%
1 month 6.18
Extreme 6.18
6.73
Current year 6.18
Extreme 6.18
7.39
1 year 5.49
Extreme 5.49
7.39
3 years 4.32
Extreme 4.32
7.39
5 years 4.21
Extreme 4.21
15.87
10 years 3
Extreme 3
17.57
Manager TitleAgeSince
Chief Executive Officer - 2018-10-31
Chief Executive Officer - 2018-06-30
Chief Tech/Sci/R&D Officer - 2021-07-31
Director TitleAgeSince
Chairman - 2023-09-26
Director/Board Member - 2021-12-31
Director/Board Member - 2024-05-22
Change 5-day change 1-year change 3-year change Capi.($)
-0.64%-.--% - - 159M
-0.64%+6.67%+53.59%+154.11% 1,070B
+0.00%+5.39%+62.89%+53.44% 611B
-0.23%+6.88%+32.14%+86.34% 445B
-1.20%-0.96%+26.12%+20.22% 329B
-1.74%-0.40%+33.19%+22.86% 290B
-1.25%+0.53%+27.68%+38.89% 287B
+2.99%+4.00%-26.09%-41.06% 213B
-0.22%+2.82%+24.37%+62.75% 195B
-0.29%+0.65%+12.75%+63.45% 157B
Average -0.32%+2.86%+27.41%+51.22% 399.58B
Weighted average by Cap. -0.42%+4.20%+38.21%+76.14%

Financials

2026 *2027 *
Net sales 658M 66.4M 58.3M 53.66M 50M 94.3M 6.31B 96.22M 645M 250M 3.1B 249M 244M 10.78B 663M 66.9M 58.74M 54.07M 50.38M 95.02M 6.36B 96.95M 650M 252M 3.12B 251M 246M 10.87B
Net income 92.33M 9.32M 8.18M 7.53M 7.02M 13.23M 886M 13.5M 90.56M 35.09M 435M 34.98M 34.23M 1.51B 45M 4.54M 3.99M 3.67M 3.42M 6.45M 432M 6.58M 44.14M 17.1M 212M 17.05M 16.68M 737M
Net Debt -242M -24.42M -21.44M -19.73M -18.39M -34.68M -2.32B -35.39M -237M -91.97M -1.14B -91.69M -89.7M -3.97B -263M -26.5M -23.27M -21.42M -19.96M -37.64M -2.52B -38.41M -258M -99.82M -1.24B -99.52M -97.37M -4.3B
Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
58.10NOK
Average target price
84.00NOK
Spread / Average Target
+44.58%

Quarterly revenue - Rate of surprise